Innate Pharma Competitors and Similar CompaniesClear all
Innate Pharma's competitors and similar companies include Ablynx, Gamida Cell, Vivia Biotech and Clasp Therapeutics.
 Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. |  Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. |  Gamida Cell Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. | |||
Founding Date | Founding Date 1999 | Founding Date 2001 | Founding Date 1998 | Founding Date 2007 | Founding Date 2020 |
Type | Type Public | Type Subsidiary | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Marseille, FR HQ Rockville, US | Locations Gent, BE HQ | Locations Boston, US HQ Jerusalem, IL | Locations Tres Cantos, ES HQ | Locations Rockville, US HQ Cambridge, US |
Employees | Employees 181 | Employees 1252% decrease | Employees 143175% increase | Employees 28 | Employees 502% increase |
Valuation ($) | Valuation ($) 148.6 m | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) €2.8m (FY, 2025) | Revenue (est.) €85.2m (FY, 2016) | Revenue (est.) $1.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods €266k (FY, 2025) | Cost of goods N/A | Cost of goods $1.5m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €8.7m (FY, 2025) | Gross profit N/A | Gross profit $330k (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income (€49.2m) (FY, 2025) | Net income (€1.1m) (FY, 2016) | Net income ($63m) (FY, 2023) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Patients Reached | Patients Reached N/A | Patients Reached 2 k (Q2, 2017) | Patients Reached 120 (Q3, 2018) | Patients Reached N/A | Patients Reached N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 9.4m (about 14 years ago) | Latest funding round $ 150m (about 2 years ago) |
Total funding raised | Total funding raised $ 94.1m | Total funding raised $ 498.8m | Total funding raised $ 128.3m | Total funding raised $ 9.4m | Total funding raised $ 150m |
For sources of this data, please see the company profile
View Company Profiles
Ablynx
HQ
Gent, BE
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View companyGamida Cell
HQ
Boston, US
Employees
143
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases.
View company
Vivia Biotech
HQ
Tres Cantos, ES
Employees
28
Vivia Biotech is a company specializing in providing individualized medicine.
View company
Clasp Therapeutics
HQ
Rockville, US
Employees
50↑ 2% increase
Clasp Therapeutics is a company that provides immuno-oncology solutions.
View company